BCTX
BriaCell Therapeutics Corp.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.40
P/S
0.00
EV/EBITDA
0.59
DCF Value
$4.22
FCF Yield
-417.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-221.7%
ROA
-129.4%
ROIC
-123.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $-7.2M | $-2.58 |
| Q1 2026 | $0.00 | $-11.4M | $-4.35 |
| Q4 2025 | $0.00 | $-11.1M | $-5.87 |
| FY 2025 | $0.00 | $-36.5M | $-86.25 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
CA
Exchange
NASDAQ
Beta
1.63
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.